AGC Biologics Inc.

Form 483 issued February 10, 2023 · Bothell, Washington

Inspection
Feb 2 – Feb 10, 2023
Observations
5
Pages
15
FEI number
3000209996

In short: On February 10, 2023, FDA issued a Form 483 with 5 observations to AGC Biologics Inc. in Bothell, Washington (FEI 3000209996) after an inspection that ran Feb 2 – Feb 10, 2023. The investigators were Andrew K. Haack, Charles Yuan-Chia Kuo, Megan Dellibovi-Ragheb, Michael Araneta and Zhong Li.

What FDA observed

Preview: the opening words of each observation
  1. 01

    Written records of investigations into unexplained discrepancies, the failure of a batch or any of its…

  2. 02

    Your firm has not established adequate procedural controls to protect the electronic data acquisition and manufacturing…

  3. 03

    There is a lack of assurance that your drug substance manufacturing operations in Building’ “at the…

  4. 04

    Standard Operating procedures or work instructions are not…

1 more observation

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at AGC Biologics Inc.?

FDA listed 5 observations on this Form 483. The opening words of each observation are shown on this page.

Who inspected AGC Biologics Inc.?

Andrew K. Haack, Charles Yuan-Chia Kuo, Megan Dellibovi-Ragheb, Michael Araneta and Zhong Li are named on this Form 483, for the inspection of Feb 2 – Feb 10, 2023. Each investigator has a profile showing what they cite most.

When was AGC Biologics Inc. inspected by FDA?

The inspection ran Feb 2 – Feb 10, 2023, and the Form 483 is dated February 10, 2023.

How do I get the full Form 483 for AGC Biologics Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free